Skip to main content
. 2020 Apr 29;24(11):6162–6177. doi: 10.1111/jcmm.15243

Figure 6.

Figure 6

RAP‐536 alleviates disease comorbidities in Hbbth3 /+ β‐thalassaemic mice. A, Effect of RAP‐536 (1 mg/kg, twice weekly for 2 months) on spleen weight. Shown are means ± SEM (n = 5 mice per group). ** P < .01 by one‐way ANOVA with post hoc Tukey HSD test. B, Effect of RAP‐536 (1 mg/kg, twice weekly for 2 months) on bone mineral density. Shown are means ± SEM (n = 5 mice per group). * P < .05 by one‐way ANOVA with post hoc Tukey HSD test